Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM Umrd4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib Plus Venetoclax Arm of the FLAIR Trial